Literature DB >> 9990695

Sample size determination for proving equivalence based on the ratio of two means for normally distributed data.

D Hauschke1, M Kieser, E Diletti, M Burke.   

Abstract

Equivalence trials aim to demonstrate that two treatments do not differ by more than a prespecified clinically irrelevant amount. We consider the problem when equivalence is defined in terms of the ratio of population means and the original (untransformed) data are normally distributed. Application of the intersection-union principle to the test proposed by Sasabuchi results in a two one-sided tests procedure of size alpha. We give the associated 100 (1-2 alpha) per cent confidence interval and derive the exact methods for calculation of power and sample sizes for the parallel group design and the two-period cross-over. We present tables and figures of required sample sizes and achieved power.

Mesh:

Substances:

Year:  1999        PMID: 9990695     DOI: 10.1002/(sici)1097-0258(19990115)18:1<93::aid-sim992>3.0.co;2-8

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  12 in total

Review 1.  Fear or favour? Statistics in pathology.

Authors:  A Wade
Journal:  J Clin Pathol       Date:  2000-01       Impact factor: 3.411

2.  Equivalence concepts in clinical trials.

Authors:  V W Steinijans; M Neuhäuser; F Bretz
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jan-Mar       Impact factor: 2.441

3.  A note on sample size calculation in bioequivalence trials.

Authors:  Dieter Hauschke
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-02       Impact factor: 2.745

4.  Population pharmacokinetic modelling of S-warfarin to evaluate the design of drug-drug interaction studies for CYP2C9.

Authors:  Kerenaftali Klein; Ivelina Gueorguieva; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-01-21       Impact factor: 2.745

5.  Design and clinical pilot testing of the model-based dynamic insulin sensitivity and secretion test (DISST).

Authors:  Thomas F Lotz; J Geoffrey Chase; Kirsten A McAuley; Geoffrey M Shaw; Paul D Docherty; Juliet E Berkeley; Sheila M Williams; Christopher E Hann; Jim I Mann
Journal:  J Diabetes Sci Technol       Date:  2010-11-01

6.  A randomized, controlled, supervised, exercise trial in young overweight men and women: the Midwest Exercise Trial II (MET2).

Authors:  Joseph E Donnelly; Richard A Washburn; Bryan K Smith; Debra K Sullivan; Cheryl Gibson; Jeffery J Honas; Matthew S Mayo
Journal:  Contemp Clin Trials       Date:  2012-04-03       Impact factor: 2.226

7.  Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials.

Authors:  Ivelina Gueorguieva; Kimberley Jackson; Steven A Wrighton; Vikram P Sinha; Jenny Y Chien
Journal:  Br J Clin Pharmacol       Date:  2010-10       Impact factor: 4.335

8.  The basel cocktail for simultaneous phenotyping of human cytochrome P450 isoforms in plasma, saliva and dried blood spots.

Authors:  Massimiliano Donzelli; Adrian Derungs; Maria-Giovanna Serratore; Christoph Noppen; Lana Nezic; Stephan Krähenbühl; Manuel Haschke
Journal:  Clin Pharmacokinet       Date:  2014-03       Impact factor: 6.447

9.  Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects.

Authors:  Manon J van der Lee; Audrey A M Blenke; Gerard A Rongen; Corrien P W G M Verwey-van Wissen; Peter P Koopmans; Cristina Pharo; David M Burger
Journal:  Antimicrob Agents Chemother       Date:  2007-09-10       Impact factor: 5.191

10.  A Multicentric, Open-Label, Randomized, Comparative Clinical Trial of Two Different Doses of Expanded hBM-MSCs Plus Biomaterial versus Iliac Crest Autograft, for Bone Healing in Nonunions after Long Bone Fractures: Study Protocol.

Authors:  Enrique Gómez-Barrena; Norma G Padilla-Eguiluz; Cristina Avendaño-Solá; Concepción Payares-Herrera; Ana Velasco-Iglesias; Ferran Torres; Philippe Rosset; Florian Gebhard; Nicola Baldini; Juan C Rubio-Suarez; Eduardo García-Rey; José Cordero-Ampuero; Javier Vaquero-Martin; Francisco Chana; Fernando Marco; Javier García-Coiradas; Pedro Caba-Dessoux; Pablo de la Cuadra; Philippe Hernigou; Charles-Henri Flouzat-Lachaniette; François Gouin; Didier Mainard; Jean Michel Laffosse; Miriam Kalbitz; Ingo Marzi; Norbert Südkamp; Ulrich Stöckle; Gabriela Ciapetti; Davide Maria Donati; Luigi Zagra; Ugo Pazzaglia; Guido Zarattini; Rodolfo Capanna; Fabio Catani
Journal:  Stem Cells Int       Date:  2018-02-22       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.